Pushkal Garg sold $422k of ALNY
CMO & EVP Dev & Med Affairs at ALNYLAM PHARMACEUTICALS, INC.. 1,682 shares at an average of $250.98, traded Nov 26, 2024, filed Nov 27, 2024.
Score components
- +15RoleOfficer
- +16Trade size$422k at market
- 0Share of holdings soldSold 8.8% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-24-000107, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | AGrant or award Common Stock | +3,434 | $0.00 | $0 | 19,139 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -30 | $247.77 | $7,433 | 19,109 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -246 | $249.60 | $61k | 18,863 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -364 | $250.68 | $91k | 18,499 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -945 | $251.42 | $238k | 17,554 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock | -97 | $252.27 | $24k | 17,457 | Nov 27, 2024 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8.4M 18,000 shares | -96% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $5.1M 11,250 shares | -40% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $633k 1,396 shares | -6% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $3.2M 6,979 shares | -11% | |
| 62Notable | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $1.0M 2,274 shares | -4% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $633k 1,396 shares | -5% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.3M 2,851 shares | -12% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Dennis A Ausiello director | $14M 31,448 shares | -97% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.